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From the 'Oxford Eye Hospital and the 2Renal Unit, Churchill Hospital, Oxford SUMMARY Plasma and aqueous levels of cyclosporin A (CsA) were determined following topical administration of CsA 1% to healthy rabbit eyes and compared with levels obtained when administered to rabbit eyes which had received corneal grafts 7-10 days previously. In addition plasma levels were determined following intramuscular administration of 50 mg CsA and the results compared with those obtained following topical administration. Topical administration to healthy rabbit eyes five times a day for three days resulted in plasma levels of CsA which were similar to those obtained over three days following an intramuscular administration of 50 mg CsA. The plasma levels in both were significantly higher than those obtained following topical administration to rabbit eyes which had received corneal grafts 7-10 days previously. Aqueous levels of CsA were lower than plasma levels, and there was no significant difference between levels obtained when CsA was administered topically to healthy eyes, to eyes which had received corneal grafts, or to the fellow eye.
Cyclosporin A (CsA) has been shown in a number of animal investigations to be effective in prolonging the survival or corneal grafts when administered intramuscularly, topically to the eye which had received the graft, or when given as a retrobulbar injection. 1`7
It has been suggested that when administered topically the drug may act locally.7 In support of this it has been reported that the survival time of corneal grafts in five rabbits was not prolonged when the CsA was administered topically to the other eye.7 It is surprising that this result was obtained, because therapeutic levels of CsA were detected in the plasma.
We decided to investigate further the plasma and aqueous levels of CsA following topical administration to rabbit eyes and to compare them with those obtained when CsA was administered intramuscularly. We considered it was important to determine the tissue levels obtained after topical administration to eyes which had recently received corneal grafts, as CsA is known to be particularly effective when administered during the first few days following an allogeneic graft."
Corrcspondcncc to T A G Bell, FRCSEd, Oxford Eye Hospital, Wsilton Strcct. Oxford OX2 6AN.
Materials and methods CYCLOSPORIN A
Cyclosporin A (Sandoz) was dissolved in arachis oil in a concentration 1 g/100 ml (= 10 g/l). The solution was heat sterilised and prepared in 10 ml bottles.
ANAESTHESIA
The animals were anaesthetised with intramuscular 'Hypnorm' (fentanyl citrate and fluanisone) 1 ml/kg. Adequate neuroleptanaesthesia was obtained to enable cornea grafts to be performed and to allow removal of samples of aqueous and blood.
CORNEAL GRAFTING
New Zealand white rabbits were killed, and 6-0 mm donor penetrating corneal grafts were trephined. Dutch rabbits of weight 2 kg were used as recipients. Guttae cyclopentolate 1% and guttae phenylephrine 10% were instilled into the eye. 10 000 units of heparin was administered intravenously to prevent aqueous clotting. The superior and inferior recti muscles were secured with 6/0 silk sutures. required, and the anterior chamber was reformed with air. Guttae chloramphenicol 0-5% was instilled and 1 mega unit of penicillin was injected intramuscularly. The lids were closed with a tarsorrhaphy stitch.
SAMPLING OF AQUEOUS AND PLASMA
Each rabbit was anaesthetised and a 25 gauge needle was inserted into the anterior chamber. 025 ml of aqueous was removed. Any sample contaminated with blood was discarded. 1 ml of blood was removed from a vein in the ear of the rabbit. Each sample was placed into a lithium heparin tube. The tubes containing blood were left at room temperature for two hours to allow CsA to equilibrate between red cells and plasma. Plasma was then separated and frozen until the assay was performed. The radioimmunoassay'" was performed with a kit provided by Sandoz Ltd, and the accuracy of the assay was monitored by control samples where the concentration of CsA was known. times a day. The intramuscular administration comprised 5 ml CsA 1% containing 50 mg CsA. Experiment 1. CsA 1% was administered topically five times a day for three days to healthy rabbit eyes. Samples of plasma and aqueous from the same eye Si convcrsion: ng/mg=gg/l. were obtained daily, and the CsA levels determined. n=5. Experiment 2. CsA 1% was administered topically five times a day for three days to healthy rabbit eyes. Samples of plasma and aqueous from the fellow unoperated eye were obtained daily and the CsA levels determined. n=3. Experiment 3. CsA was administered topically five times a day for three days to rabbits which had received a corneal graft 7-10 days previously. Samples of plasma and aqueous from the eye containing the graft were obtained daily and the CsA levels determined. n=6. Experiment 4. An intramuscular injection of 50 mg CsA was administered to each of three rabbits. Samples of plasma were obtained subsequently daily for three days and the CsA levels determined. n=3.
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Results
Figs. 1-3 demonstrate the plasma and aqueous levels of CsA following the topical administration of CsA, and Fig. 4 the plasma level of CsA obtained on three days following single intramuscular injection of 50 mg CsA. Table 1 Fig. 4 Plasma levels of CsA obtained on the three days following an intramuscular injection of5O mg CsA.
The plasma levels of CsA following topical administration to healthy eyes (Figs. 1, 2 ) were significantly higher (p<0-01, Wilcoxon rank test) than the plasma levels following topical administration to eyes which had received corneal grafts (Fig.   3 ).
There was no significant difference between the plasma levels of CsA measured over the three days following an intramuscular injection of 50 mg, CsA (Fig. 4 ) and the plasma level measured daily on the rabbits which received topical CsA five times a day to healthy eyes (Figs. 1, 2) (Wilcoxon rank test).
The plasma levels of CsA within the group which received the intramuscular CsA (Fig. 4 ) were significantly higher than the plasma levels in the group which received topical CsA five times a day to the eye which had received the corneal graft ( Fig. 3) (0.02> p>0 01, Student's t test). There was no significant difference between the aqueous levels shown in Figs.  1, 2 , and 3.
Discussion
The investigation confirms the findings by Foets et al.47 that systemic levels of CsA are recorded when CsA is administered topically to rabbit eyes. A single intramuscular injection of 25 mg/kg CsA results in a plasma level which is less than that normally considered therapeutic, namely > 100 mg/l. " This plasma level tends to persist at least over three days. Aqueous levels of CsA following topical administration are lower than plasma levels and appear to be uninfluenced by the presence of a corneal graft or when the CsA is administered to the other eye.
As the plasma level of CsA following topical administration to healthy rabbit eyes is found to be similar to that following an intramuscular injection of CsA, this suggests that sufficient CsA is absorbed to act systemically. As less CsA is absorbed when administered topically in the early postgraft period, then clearly the conditions do not favour absorption, as might be expected, but reduce the absorption.
It is possible that topical administration in the early postgraft period is ineffective, as the absorption is reduced. It should be noted that, when Foets et al.7 administered CsA topically to the fellow eye in a rabbit which had received a corneal graft, the fellow eye had also been operated on. It is possible that the failure to prevent rejection may have been due to poor absorption of CsA from the injured fellow eye in the early postgraft period. Topical administration of CsA to an uninjured eye would appear in the animal model to be a potentially useful mode of administering CsA. Clearly further investigation is required to determine whether this is true in the human. In relation to corneal grafting, unless clear evidence of a local action can be demonstrated, it is possible it may be of little use in the early postgraft period. Administration to the unaffected eye or systemic administration would appear to be more suitable methods of giving the drug during this important period.
